June 1, 2022
Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
MYD88 Tumors
Read More
June 1, 2022
Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL
LGL-L
PTCL
Solid Tumors
Read More
May 31, 2022
STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis
European Alliance of Associations for Rheumatology (EULAR) 2022 Annual Congress
Read More
May 17, 2022
Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets
Society for Investigative Dermatology (SID) 2022 Annual Meeting
Read More
May 10, 2022
Non-Clinical Safety Considerations when Developing Targeted Protein Degraders
Applied Pharmaceutical Toxicology (APT) 2022
Read More
May 3, 2022
Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition
The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
May 3, 2022
STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation
The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
April 27, 2022
Drugging Tissue Restricted E3 Ligases for TPD-based Precision Medicine
2nd Annual Ligase Targeting Drug Development Summit
Read More
April 26, 2022
Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics
2nd Annual Ligase Targeting Drug Development Summit
Read More
April 7, 2022
KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
American Association for Cancer Research Annual Meeting
Liquid Tumors
Solid Tumors
Read More